Soon after HIV was discovered as the cause of AIDS in 1983–1984, there was an
expectation that a preventive vaccine would be rapidly developed. In trying to achieve that …

In this review, we describe the most recent advances in the use of animal models for
HIV/AIDS research, and will break down these advances in three areas: models for virus …

Natural killer (NK) cells have traditionally been considered nonspecific components of
innate immunity, but recent studies have shown features of antigen-specific memory in …

Long-term in vivo expression of a broad and potent entry inhibitor could circumvent the need
for a conventional vaccine for HIV-1. Adeno-associated virus (AAV) vectors can stably …

ABSTRACT Anti-HIV-1 envelope glycoprotein (Env) antibodies without broadly neutralizing
activity correlated with protection in the RV144 clinical trial, stimulating interest in other …

Antibodies are the primary correlate of protection for most licensed vaccines; however, their
mechanisms of protection may vary, ranging from physical blockade to clearance via the …

Recent studies have linked antibody Fc-mediated effector functions with protection or control
of human immunodeficiency type 1 (HIV-1) and simian immunodeficiency (SIV) infections …

Human immunodeficiency virus (HIV) infection induces immunological dysfunction, which
limits the elimination of HIV-infected cells during treated infection. Identifying and targeting …

Tetherin is an IFN-inducible transmembrane protein that inhibits the detachment of
enveloped viruses from infected cells. HIV-1 overcomes this restriction factor by expressing …

Although antibodies to the human immunodeficiency virus type 1 (HIV-1) envelope
glycoprotein have been studied extensively for their ability to block viral infectivity, little data …